Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Webcast: Current Best Practice and Emerging Strategies for Pulmonary Arterial Hypertension
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: April 15, 2021 Expiration: April 14, 2022
Start Activity
Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Vallerie V. McLaughlin, MD
Ioana R. Preston, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recognize risk factors for PAH
  • Recognize the signs and symptoms of PAH that would lead to an earlier and accurate diagnosis of PAH
  • Differentiate the efficacy and safety data of currently available treatments for PAH management
  • Formulate treatment plans for PAH management based on individual patient factors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Vallerie V. McLaughlin, MD

Kim A. Eagle Endowed Professor of Cardiovascular Medicine
Associate Chief Clinic Officer
Cardiovascular Medicine, Internal Medicine
University of Michigan
Ann Arbor, Michigan

Vallerie V. McLaughlin, MD, has disclosed that she has received funds for research support from Acceleron, Actelion, CiVi Biopharma, Gilead Sciences, Gossamer Bio, and United Therapeutics and consulting fees from Acceleron, Actelion, Altavant, Reata, Sunovion, and United Therapeutics.
Ioana R. Preston, MD

Associate Professor of Medicine
Pulmonary, Critical Care and Sleep Division
Tufts Medical Center
Director, PH Center
Tufts University School of Medicine
Boston, Massachusetts

Ioana R. Preston, MD, has disclosed that she has received funds for research support from Acceleron, Actelion, PhaseBio, and United Therapeutics and consulting fees from Acceleron, Actelion, Pfizer, and United Therapeutics.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pulmonologists, cardiologists, and other healthcare professionals who care for patients with PAH.

Goal

The goal of this activity is to increase the knowledge and competence of learners to recognize and diagnose PAH and develop individualized treatment plans to improve patient outcomes.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 15, 2021, through April 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

PAH-Directed Therapies
  • CME

Loading...
Listen to this expert discussion on identifying and managing PAH, including earlier and accurate diagnosis, treatment approaches, and the impact of disease progression.
Vallerie V. McLaughlin, MD
Ioana R. Preston, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: April 15, 2021 Expiration: April 14, 2022

This program is divided into several short segments that you can step through using the Video Chapters menu.

Related Content

James C. Coons, PharmD, FCCP, BCCP; Martha Kingman, DNP, FNP-C; and Vallerie McLaughlin, MD, answer questions from a ProCE webinar on considerations in PAH

James C. Coons, PharmD, FCCP, BCCP Martha Kingman, DNP, FNP-C Vallerie V. McLaughlin, MD Released: March 30, 2021

CCO slides from Vallerie McLaughlin, MD, and Ioana Preston, MD. Identifying and managing pulmonary arterial hypertension (PAH)

Vallerie V. McLaughlin, MD Ioana R. Preston, MD Released: March 25, 2021

Video Chapters


Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue